ELCO Management Co. LLC purchased a new stake in shares of Allergan PLC. (NYSE:AGN) during the third quarter, Holdings Channel reports. The firm purchased 6,495 shares of the company’s stock, valued at approximately $1,496,000.
Several other institutional investors have also modified their holdings of the stock. Sfmg LLC acquired a new position in shares of Allergan PLC. during the third quarter valued at about $1,759,000. Barnett & Company Inc. raised its position in shares of Allergan PLC. by 4.9% in the third quarter. Barnett & Company Inc. now owns 1,079 shares of the company’s stock valued at $249,000 after buying an additional 50 shares during the last quarter. Ashburton Jersey Ltd acquired a new position in shares of Allergan PLC. during the third quarter valued at about $581,000. First Heartland Consultants Inc. raised its position in shares of Allergan PLC. by 13.0% in the third quarter. First Heartland Consultants Inc. now owns 6,342 shares of the company’s stock valued at $1,461,000 after buying an additional 730 shares during the last quarter. Finally, HighPoint Advisor Group LLC raised its position in shares of Allergan PLC. by 3.0% in the third quarter. HighPoint Advisor Group LLC now owns 1,197 shares of the company’s stock valued at $239,000 after buying an additional 35 shares during the last quarter. Institutional investors own 86.40% of the company’s stock.
Allergan PLC. (NYSE:AGN) opened at 246.76 on Tuesday. The firm has a market capitalization of $92.55 billion, a P/E ratio of 6.46 and a beta of 1.07. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $301.32. The company’s 50-day moving average price is $220.50 and its 200-day moving average price is $222.70.
Allergan PLC. (NYSE:AGN) last posted its earnings results on Wednesday, February 8th. The company reported $3.90 EPS for the quarter, topping analysts’ consensus estimates of $3.76 by $0.14. Allergan PLC. had a net margin of 100.04% and a return on equity of 7.21%. The business earned $3.86 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the previous year, the firm posted $3.41 EPS. The firm’s revenue was up 7.1% on a year-over-year basis. Equities research analysts expect that Allergan PLC. will post $16.03 earnings per share for the current fiscal year.
This report was posted by sleekmoney and is owned by of sleekmoney. If you are viewing this report on another site, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this report can be viewed at http://sleekmoney.com/elco-management-co-llc-purchases-shares-of-6495-allergan-plc-agn/1659966.html.
Several brokerages have recently issued reports on AGN. Credit Suisse Group reiterated a “buy” rating and issued a $274.00 price target on shares of Allergan PLC. in a research note on Tuesday. Leerink Swann boosted their price objective on Allergan PLC. to $280.00 and gave the stock a “buy” rating in a research report on Thursday, February 9th. Mizuho restated a “buy” rating and set a $275.00 price objective (up previously from $273.00) on shares of Allergan PLC. in a research report on Tuesday, February 7th. Vetr lowered Allergan PLC. from a “buy” rating to a “hold” rating and set a $228.27 price objective on the stock. in a research report on Wednesday, February 1st. Finally, Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $250.00 price objective (up previously from $240.00) on shares of Allergan PLC. in a research report on Wednesday, January 18th. Eight equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. Allergan PLC. has a consensus rating of “Buy” and an average target price of $272.01.
In other news, Director Nesli Basgoz sold 500 shares of the business’s stock in a transaction on Thursday, December 8th. The shares were sold at an average price of $188.72, for a total transaction of $94,360.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Brent L. Saunders acquired 5,250 shares of the business’s stock in a transaction dated Monday, November 21st. The shares were acquired at an average cost of $189.13 per share, with a total value of $992,932.50. The disclosure for this purchase can be found here. Insiders own 0.27% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/elco-management-co-llc-purchases-shares-of-6495-allergan-plc-agn/1659966.html
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.